Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
289–324
Headlines
595
Sources here
4
Companies here
25
Current section Brazil Healthcare news

Chronological news

Earlier headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?

Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. …

MRCK34 mentioned PFIZ34 mentioned
Sharemaestro market context Trend signal active 52 weeks +46.5% MRCK34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?

Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a …

VRTX34 main company
Sharemaestro market context Price above Trend Line 52 weeks +17.4% · Next-week setup positive 55.7% VRTX34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?

Abbott Laboratories' ABT Medical Devices remains its largest segment and continues to benefit from a strong pipeline of new product launches and growing adoption across cardiovascular care and diabetes management. The segment is well positioned to capitalize on the expanding global medical devices market. …

ABTT34 mentioned B1SX34 mentioned
Sharemaestro market context Price above Trend Line 52 weeks -21.9% ABTT34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?

Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares …

JNJB34 mentioned I1SR34 mentioned MDTC34 mentioned
Sharemaestro market context Trend signal active 52 weeks +40.9% · Next-week setup negative 44.7% JNJB34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading

LILY34 mentioned N1VO34 mentioned VRTX34 mentioned
Sharemaestro market context Trend signal active 52 weeks +61.5% LILY34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Lifespan Vision Ventures Leads Remedium Bio's Series A Financing

Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial …

LILY34 mentioned
Sharemaestro market context Trend signal active 52 weeks +61.5% LILY34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

We Said These 4 Dividend Aristocrats Could Soar. Here’s How They Did, Plus 3 New Picks.

Quick Read ABBV surged 47% and BDX gained 26% over the past year, both decisively beating the market as their overlooked dividend growth drove outsized returns. All four original picks kept raising dividends regardless of price, with PG marking its 70th consecutive year of …

MDTC34 mentioned
Sharemaestro market context Price below Trend Line 52 weeks -10.3% MDTC34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Wall Street Bulls Look Optimistic About Veeva (VEEV): Should You Buy?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Let's …

V2EE34 mentioned
Sharemaestro market context Price above Trend Line 52 weeks -28.3% · Next-week setup negative 35.8% V2EE34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. Continue Reading

VRTX34 main company
Sharemaestro market context Price above Trend Line 52 weeks +17.4% · Next-week setup positive 55.7% VRTX34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength …

PFIZ34 main company LILY34 mentioned N1VO34 mentioned B1NT34 mentioned
Sharemaestro market context Price above Trend Line 52 weeks +4.1% PFIZ34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Zoetis (ZTS) Looked Like a Winner. What Went Wrong?

Brown Advisory, an investment management company, released its "Brown Advisory Global Leaders Strategy" for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory's Global Leaders Strategy delivered a net return of 4.6% in the second …

Z1TS34 main company
Sharemaestro market context Price below Trend Line 52 weeks -55.1% Z1TS34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.BioMarin Pharmaceutical logo An audio webcast of the presentation …

B1MR34 main company
Sharemaestro market context Price above Trend Line 52 weeks +3.3% · Next-week setup negative 37.8% B1MR34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which …

JNJB34 main company I1SR34 main company
Sharemaestro market context Trend signal active 52 weeks +40.9% · Next-week setup negative 44.7% JNJB34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Beat the Market Like Zacks: Aveanna, FactSet, Shopify in Focus

Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively. Wall Street's strong weekly performance was driven by renewed investor optimism over the U.S. …

TMOS34 mentioned
Sharemaestro market context Price above Trend Line 52 weeks +14.1% TMOS34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

VAREX IMAGING (VREX) Q3 Earnings Beat Estimates

VAREX IMAGING (VREX) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

MDTC34 mentioned
Sharemaestro market context Price below Trend Line 52 weeks -10.3% MDTC34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

Revvity's new maternal and fetal biochemistry testing platform Designed for accessibility, simplicity, and flexibility Purpose-built for small to mid-sized labs and clinics to enable this capability in-house for the first time WALTHAM, Mass., August 10, 2026--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the …

R1VT34 main company
Sharemaestro market context Trend signal active 52 weeks +22.8% · Next-week setup negative 34.8% R1VT34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

1 Profitable Stock on Our Buy List and 2 We Find Risky

1 Profitable Stock on Our Buy List and 2 We Find Risky While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, "Your margin is my opportunity". …

R1VT34 mentioned
Sharemaestro market context Trend signal active 52 weeks +22.8% · Next-week setup negative 34.8% R1VT34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers

Agreement supports ACCESS-affiliated ASCs in adopting the CARTO™ System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio …

JNJB34 mentioned
Sharemaestro market context Trend signal active 52 weeks +40.9% · Next-week setup negative 44.7% JNJB34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Resmed’s stock falls by 7% on soft FY27 outlook

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares …

R1MD34 main company
Sharemaestro market context Price below Trend Line 52 weeks -36.2% · Next-week setup negative 26.8% R1MD34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read …

N1VO34 mentioned
Sharemaestro market context Price above Trend Line 52 weeks -13.6% N1VO34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading

LILY34 main company N1VO34 mentioned
Sharemaestro market context Trend signal active 52 weeks +61.5% LILY34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance

ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance Animal health company Zoetis (NYSE:ZTS) fell short of the market's revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company's full-year revenue guidance of $9.22 billion at …

Z1TS34 mentioned
Sharemaestro market context Price below Trend Line 52 weeks -55.1% Z1TS34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon.com Inc.'s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced …

LILY34 mentioned N1VO34 mentioned
Sharemaestro market context Trend signal active 52 weeks +61.5% LILY34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?

Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world's largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but …

TMOS34 main company DHER34 mentioned
Sharemaestro market context Price above Trend Line 52 weeks +14.1% TMOS34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Is Medtronic (MDT) Becoming a Turnaround Story?

UBS upgraded Medtronic (NYSE:MDT) to a Buy from Neutral today, telling investors in a research note that a "turnaround" is underway at the company. The upgrade raises an important question for investors: Is Medtronic finally returning to sustainable growth after years of underperformance, or …

MDTC34 main company
Sharemaestro market context Price below Trend Line 52 weeks -10.3% MDTC34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +14.4% ABBV34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

3 S&P 500 Stocks We Approach with Caution

3 S&P 500 Stocks We Approach with Caution While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds. Picking the right …

C1NC34 mentioned
Sharemaestro market context Trend signal active 52 weeks +117.4% C1NC34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

UnitedHealth (UNH) Commits $4M to Tennessee Health Hub Expansion

On July 29, UnitedHealth Group (NYSE:UNH) announced a $4 million commitment, funded through the United Health Foundation, to expand the University of Tennessee Health Sciences' health hub network from 5 locations to 13 across the state by the end of 2027, a buildout expected …

UNHH34 main company
Sharemaestro market context Trend signal active 52 weeks +26.7% UNHH34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context